CN102552811A - Oral Chinese medicine composition for treating apoplexy - Google Patents
Oral Chinese medicine composition for treating apoplexy Download PDFInfo
- Publication number
- CN102552811A CN102552811A CN201210023514XA CN201210023514A CN102552811A CN 102552811 A CN102552811 A CN 102552811A CN 201210023514X A CN201210023514X A CN 201210023514XA CN 201210023514 A CN201210023514 A CN 201210023514A CN 102552811 A CN102552811 A CN 102552811A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- oral chinese
- oral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 39
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 208000006011 Stroke Diseases 0.000 title claims abstract description 20
- 206010008190 Cerebrovascular accident Diseases 0.000 title claims abstract description 19
- 241000237903 Hirudo Species 0.000 claims abstract description 15
- 210000000582 semen Anatomy 0.000 claims abstract description 15
- 239000000843 powder Substances 0.000 claims abstract description 8
- 239000006187 pill Substances 0.000 claims abstract description 6
- 235000014375 Curcuma Nutrition 0.000 claims abstract description 5
- 241000219780 Pueraria Species 0.000 claims abstract description 5
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 4
- 239000002775 capsule Substances 0.000 claims abstract description 3
- 239000007788 liquid Substances 0.000 claims abstract description 3
- 239000007901 soft capsule Substances 0.000 claims abstract description 3
- 241000756943 Codonopsis Species 0.000 claims description 14
- 241000237636 Pheretima Species 0.000 claims description 14
- 241000522620 Scorpio Species 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 12
- 239000009636 Huang Qi Substances 0.000 claims description 10
- 239000009490 scorpio Substances 0.000 claims description 10
- 239000008187 granular material Substances 0.000 claims description 6
- 241000407170 Curcuma Species 0.000 claims description 4
- 241000545442 Radix Species 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 11
- 210000004369 blood Anatomy 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 9
- 239000000463 material Substances 0.000 abstract description 2
- 241000544682 Acorus tatarinowii Species 0.000 abstract 1
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 241000045403 Astragalus propinquus Species 0.000 abstract 1
- 241000255789 Bombyx mori Species 0.000 abstract 1
- 241000007126 Codonopsis pilosula Species 0.000 abstract 1
- 244000163122 Curcuma domestica Species 0.000 abstract 1
- 241000657528 Dalbergia odorifera Species 0.000 abstract 1
- 241000112528 Ligusticum striatum Species 0.000 abstract 1
- 241000361919 Metaphire sieboldi Species 0.000 abstract 1
- 235000017276 Salvia Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 241000239226 Scorpiones Species 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
- YSEXMKHXIOCEJA-FVFQAYNVSA-N Nicergoline Chemical compound C([C@@H]1C[C@]2([C@H](N(C)C1)CC=1C3=C2C=CC=C3N(C)C=1)OC)OC(=O)C1=CN=CC(Br)=C1 YSEXMKHXIOCEJA-FVFQAYNVSA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 239000004677 Nylon Substances 0.000 description 5
- 210000000269 carotid artery external Anatomy 0.000 description 5
- 210000004004 carotid artery internal Anatomy 0.000 description 5
- 229920001778 nylon Polymers 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 3
- 201000006474 Brain Ischemia Diseases 0.000 description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 229960000715 nimodipine Drugs 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 210000002551 anterior cerebral artery Anatomy 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000001168 carotid artery common Anatomy 0.000 description 2
- 238000009499 grossing Methods 0.000 description 2
- 210000003657 middle cerebral artery Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000213006 Angelica dahurica Species 0.000 description 1
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013642 Drooling Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241000531807 Psophiidae Species 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000008630 Sialorrhea Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses an oral Chinese medicine composition for treating apoplexy. The oral Chinese medicine composition has the effects of tonifying qi and blood, and dispelling stasis and freeing channels, and is used for treating apoplexy with blood-stasis obstruction. The oral Chinese medicine composition comprises Astragalus mongholicus, Angelica sinensis, Ligusticum wallichii, Pueraria, Salvia Miltiorrhizae, hirudo, scorpion, Earthworm, Acorus tatarinowii, Radix Curcuma, Codonopsis pilosula, Bombyx mori, Semen Ziziphi Spinosae, and Dalbergia Odorifera. The oral Chinese medicine composition can be made into clinically acceptable tablets, particulate agents, pills, capsules, dripping pills, soft capsules, sustained release agents, oral liquids or freeze-dried powder injection, etc. according to routine technology by adding routine auxiliary materials.
Description
Technical field
The present invention relates to the field of Chinese medicines, specifically, relate to a kind of oral Chinese medicine compositions of treating apoplexy.
Background technology
Apoplexy (cerebrovascular disease) is clinical commonly encountered diseases and frequently-occurring disease, and its mortality rate is high, disability rate is high, has brought white elephant for family and society.Add up according to interrelated data; The change of Along with people's life style; China has become the hotspot of this type disease, and doctor trained in Western medicine adopts treatment meanss such as thrombolytic therapy and anticoagulant therapy more, and these methods have certain curative effect; But exist weak, slow, the shortcoming such as the treatment phase is long that takes effect of curative effect, but also can cause side effect such as subcutaneous hemorrhage, gastrointestinal hemorrhage, cerebral hemorrhage.
In recent years, China's medical circle is given full play to the advantage of Chinese medicine, and apoplexy has been carried out deep basic research and clinical research.The traditional Chinese medical science medicine of present existing treatment apoplexy has all been obtained effect preferably in clinical practice, receive patient's popular welcome.But be not difficult to find out that also the oral formulations ubiquity crude drug content of treating apoplexy at present is on the low side, absorb slowly the shortcoming that onset is also slow.Therefore, develop high, the rapid-action medicine of crude drug content, have very important significance to adapt to clinical needs.
Summary of the invention
The object of the invention is exactly for fear of providing a kind of crude drug content high with the shortcoming and defect that overcomes prior art, and convenient oral is rapid-action, the traditional Chinese medical science oral drugs of the treatment apoplexy that curative effect is high.
A kind of oral Chinese medicine compositions of treating apoplexy involved in the present invention, it mainly is by the crude drug Radix Astragali, Radix Angelicae Sinensis, Rhizoma Chuanxiong, Radix Puerariae, Radix Salviae Miltiorrhizae, Hirudo, Scorpio, Pheretima, Rhizoma Acori Graminei, Radix Curcumae, Radix Codonopsis, Periostachum bombycis, Semen Ziziphi Spinosae, Lignum Dalbergiae Odoriferae are processed.
The card that prescription according to the invention cures mainly is by due to the venation block, and the Radix Astragali, Radix Codonopsis play flaccidity with invigorating primordial QI useless, makes the prosperous blood of gas capable; Chinese Angelica blood replonishing is aided with Rhizoma Chuanxiong, Radix Salviae Miltiorrhizae to make strengthening spleen and nourishing blood; Be aided with Lignum Dalbergiae Odoriferae, Hirudo is enriched blood and invigorates blood circulation; Scorpio, Pheretima, Periostachum bombycis, Radix Puerariae are played the merit of the spasmolytic that relieves dizziness, high fever, infantile convulsions, epilepsy, etc., removing obstruction in the collateral to relieve pain altogether; Rhizoma Acori Graminei, Radix Curcumae to be making to have one's ideas straightened out the merit of refreshment, and have removing dampness concurrently, the effect of eliminating phlegm; The Semen Ziziphi Spinosae convergence motive is with tranquilizing mind.Full side share, and plays blood circulation promoting and blood stasis dispelling altogether, the effect of dredge the meridian passage
Benefiting QI and nourishing blood of the present invention, eliminating blood stasis and smoothing collaterals.Stagnation of the stroke for the context, Zheng Jian hemiplegia, aphasia sound dumb, mouth askew, partial body numbness, shortness of breath, fatigue, palpitations, Koushi white, from sweating, foot swelling, loose stools, mouth drooling, tongue dim, greasy or scalloped tongue, thin pulse by.
The consumption of its drug component of Chinese medicine composition of the present invention is also groped to sum up to draw through the inventor in a large number
A kind of proportion of composing of treating the oral Chinese medicine compositions of apoplexy of described treatment comprises: Radix Astragali 10-50 part, Radix Angelicae Sinensis 5-20 part, Rhizoma Chuanxiong 5-20 part, Radix Puerariae 5-20 part; Radix Salviae Miltiorrhizae 5-20 part, Hirudo 5-20 part, Scorpio 5-20 part; Pheretima 5-20 part; Rhizoma Acori Graminei 5-20 part, Radix Curcumae 5-20 part, Radix Codonopsis 5-10 part, Periostachum bombycis 5-10 part, Semen Ziziphi Spinosae 5-10 part, Lignum Dalbergiae Odoriferae 1-3 part.
A kind of further proportion of composing of treating the oral Chinese medicine compositions of apoplexy of described treatment comprises: Radix Astragali 20-30 part, Radix Angelicae Sinensis 10-15 part, Rhizoma Chuanxiong 10-15 part, Radix Puerariae 10-15 part; Radix Salviae Miltiorrhizae 10-15 part, Hirudo 10-15 part, Scorpio 10-15 part; Pheretima 10-15 part; Rhizoma Acori Graminei 10-15 part, Radix Curcumae 10-15 part, Radix Codonopsis 8-12 part, Periostachum bombycis 8-12 part, Semen Ziziphi Spinosae 6-8 part, Lignum Dalbergiae Odoriferae 1-2 part.
A kind of preferred proportion of composing of treating the oral Chinese medicine compositions of apoplexy of described treatment comprises: 25 parts of the Radixs Astragali, 12 parts of Radix Angelicae Sinensis, 15 parts of Rhizoma Chuanxiongs, 15 parts of Radix Puerariaes; 10 parts of Radix Salviae Miltiorrhizaes, 10 parts of Hirudos, 10 parts of Scorpios; 10 parts of Pheretimas; 10 parts of Rhizoma Acori Graminei, 10 parts of Radix Curcumaes, 8 parts of Radix Codonopsis, 8 parts of Periostachum bombycis, 8 parts of Semen Ziziphi Spinosaes, 1 part of Lignum Dalbergiae Odoriferae.
A kind of preferred proportion of composing of treating the oral Chinese medicine compositions of apoplexy of described treatment can also comprise: 30 parts of the Radixs Astragali, 15 parts of Radix Angelicae Sinensis, 15 parts of Rhizoma Chuanxiongs, 10 parts of Radix Puerariaes; 10 parts of Radix Salviae Miltiorrhizaes, 10 parts of Hirudos, 10 parts of Scorpios; 10 parts of Pheretimas; 10 parts of Rhizoma Acori Graminei, 10 parts of Radix Curcumaes, 12 parts of Radix Codonopsis, 10 parts of Periostachum bombycis, 8 parts of Semen Ziziphi Spinosaes, 2 parts of Lignum Dalbergiae Odoriferaes.
In a word, the present invention forms monarch, minister, it is various to help, make, and compatibility is rigorous, complements each other, and plays benefiting QI and nourishing blood altogether, the merit of eliminating blood stasis and smoothing collaterals.
Medicine of the present invention can add conventional adjuvant, according to common process, processes clinical acceptable tablet, granule, pill, capsule, drop pill, soft capsule, slow releasing agent, oral liquid or lyophilized injectable powder etc.
The specific embodiment
Following examples are used to explain the present invention, but are not used for limiting scope of the present invention.
Embodiment 1
1, prescription:
Radix Astragali 25g, Radix Angelicae Sinensis 12g, Rhizoma Chuanxiong 15g, Radix Puerariae 15g, Radix Salviae Miltiorrhizae 10g, Hirudo 10g, Scorpio 10g, Pheretima 10g, Rhizoma Acori Graminei 10g, Radix Curcumae 10g, Radix Codonopsis 8g, Periostachum bombycis 8g, Semen Ziziphi Spinosae 8g, Lignum Dalbergiae Odoriferae 1g.
2. method for making:
More than 14 the flavor be ground into fine powder, sieve, mixing, the system granule, drying, encapsulated, process 300, promptly get.
Embodiment 2
1, prescription:
Radix Astragali 30g, Radix Angelicae Sinensis 15g, Rhizoma Chuanxiong 15g, Radix Puerariae 10g, Radix Salviae Miltiorrhizae 10g, Hirudo 10g, Scorpio 10g, Pheretima 10g, Rhizoma Acori Graminei 10g, Radix Curcumae 10g, Radix Codonopsis 12g, Periostachum bombycis 10g, Semen Ziziphi Spinosae 8g, Lignum Dalbergiae Odoriferae 2g.
2, technology:
More than 14 the flavor, be ground into fine powder, sieve, mixing, the system granule, drying, tabletting is processed 300, promptly gets.
Embodiment 3
1, prescription:
Radix Astragali 28g, Radix Angelicae Sinensis 18g, Rhizoma Chuanxiong 12g, Radix Puerariae 15g, Radix Salviae Miltiorrhizae 10g, Hirudo 10g, Scorpio 8g, Pheretima 8g, Rhizoma Acori Graminei 8g, Radix Curcumae 8g, Radix Codonopsis 8g, Periostachum bombycis 5g, Semen Ziziphi Spinosae 5g, Lignum Dalbergiae Odoriferae 1g.
2. method for making:
More than 14 the flavor, be ground into fine powder, sieve, mixing, the system granule, drying, encapsulated, process 300, promptly get.
Embodiment 4
1, prescription:
Radix Astragali 20g, Radix Angelicae Sinensis 10g, Rhizoma Chuanxiong 10g, Radix Puerariae 8g, Radix Salviae Miltiorrhizae 8g, Hirudo 5g, Scorpio 5g, Pheretima 5g, Rhizoma Acori Graminei 5g, Radix Curcumae 5g, Radix Codonopsis 10g, Periostachum bombycis 5g, Semen Ziziphi Spinosae 8g, Lignum Dalbergiae Odoriferae 3g.
2. method for making:
More than 14 the flavor be ground into fine powder, sieve, mixing, the system granule, drying, tabletting is processed 300, promptly gets.
The test of pesticide effectiveness of embodiment 5 sermion tablets
[test material]
Receive the reagent thing: sermion tablet: chocolate brown powder, the 0.5g/ sheet is made by embodiment 2, is made into required concentration with preceding with distilled water.
Positive control drug: nimodipine, Tianjin Central Pharmaceutical Co., Ltd, lot number 2010050908
[test method and result]
1. to the protective effect of acute experiment property imperfection cerebral ischemia mice
Get 80 of IC R mices, male and female have both, and are divided into 5 groups at random.Model group: give isometric distilled water; Positive drug group: give nimodipine 40m g/kg, sermion tablet low dose group 4g/kg, sermion tablet high dose group 8g/kg; Oral successive administration 7 days; After 0.5 hour, dorsal position is fixed in the last administration, with cutting off in the middle of 0 trumpeter's art suture two ends ligation bilateral common carotid arteries (merging vagus nerve) back.The breathing of record mice is held time.
The result sees table 1.
Table 1 sermion tablet is to the protective effect of chmice acute cerebral ischemia
Annotate: compare with model group,
△P＜0.05,
△ △P＜0.01.
2. to the protective effect of middle cerebral artery ischemia-reperfusion rat due to suture method
Will long 40mm, an end of the nylon wire of diameter 0.2mm is heated to be slick sphere.Clean and with wipes of alcohol in 18.5mm place labelling apart from the pommel, place 0.9%NS subsequent use.The duplicating and divide into groups of intraluminal middle cerebral artery occlusion in rats ischemia-reperfusion injury model: get 70 of rats, be divided into 6 groups at random, except that 10 of sham operated rats, all the other 5 groups every group 15.Sham operated rats, model group: give isometric distilled water, the positive drug group: give nimodipine 20mg/kg, sermion tablet high dose group 12g/kg, sermion tablet low dose group 6g/kg.Each organizes oral successive administration 7 days, after 0.5 hour, uses 10% chloral hydrate in the last administration, 300mg/kg, intraperitoneal injection of anesthesia.Lie on the back on operating-table, neck medisection is separated left carotid (CCA), external carotid artery (ECA), and internal carotid artery (ICA) meets the branch of pricking and cutting off ECA with No. 0 line, separates the outer branch of the cranium pterygoid process arteria palatina of ICA.Folder closes CCA, ICA, and ready nylon embolus is inserted the people from ECA, goes into cranium to anterior cerebral artery (ACA) through the CCA crotch through ICA, and the nylon wire insertion depth is about 18mm.The blood that draws nylon wire that its pommel is back to when pouring into again outward can to recover middle cerebral artery in the ECA supplies.It is the same that sham operated rats is not inserted outer all the other steps of nylon wire.
Result of the test is seen table 2.
Table 2 sermion tablet is to the influence of ischemia-reperfusion rat brain index and brain water content
Annotate: compare with sham operated rats,
△P＜0.05,
△ △P＜0.01
Compare with model group,
*P＜0.05,
*P＜0.01
This experimental result shows that sermion tablet can obviously reduce cerebral index and the brain water content of ischemia-reperfusion rat, obviously prolongs the breathing time that the ligation bilateral common carotid arteries causes acute incomplete cerebral ischemia mice.The expansible cerebrovascular of sermion tablet is described, is improved cerebral blood flow, improve brain function.
Claims (5)
1. oral Chinese medicine compositions of treating apoplexy, the composition and the weight portion that it is characterized in that processing the crude drug of this medicine are Radix Astragali 10-50 part, Radix Angelicae Sinensis 5-20 part, Rhizoma Chuanxiong 5-20 part, Radix Puerariae 5-20 part, Radix Salviae Miltiorrhizae 5-20 part; Hirudo 5-20 part; Scorpio 5-20 part, Pheretima 5-20 part, Rhizoma Acori Graminei 5-20 part; Radix Curcumae 5-20 part, Radix Codonopsis 5-10 part, Periostachum bombycis 5-10 part, Semen Ziziphi Spinosae 5-10 part, Lignum Dalbergiae Odoriferae 1-3 part.
2. a kind of oral Chinese medicine compositions of treating apoplexy according to claim 1, composition and the weight portion of processing the crude drug of this medicine are Radix Astragali 20-30 part, Radix Angelicae Sinensis 10-15 part, Rhizoma Chuanxiong 10-15 part, Radix Puerariae 10-15 part, Radix Salviae Miltiorrhizae 10-15 part; Hirudo 10-15 part; Scorpio 10-15 part, Pheretima 10-15 part, Rhizoma Acori Graminei 10-15 part; Radix Curcumae 10-15 part, Radix Codonopsis 8-12 part, Periostachum bombycis 8-12 part, Semen Ziziphi Spinosae 6-8 part, Lignum Dalbergiae Odoriferae 1-2 part.
3. a kind of oral Chinese medicine compositions of treating apoplexy according to claim 2, composition and the weight portion of processing the crude drug of this medicine are 25 parts of the Radixs Astragali, 12 parts of Radix Angelicae Sinensis, 15 parts of Rhizoma Chuanxiongs, 15 parts of Radix Puerariaes, 10 parts of Radix Salviae Miltiorrhizaes; 10 parts of Hirudos; 10 parts of Scorpios, 10 parts of Pheretimas, 10 parts of Rhizoma Acori Graminei; 10 parts of Radix Curcumaes, 8 parts of Radix Codonopsis, 8 parts of Periostachum bombycis, 8 parts of Semen Ziziphi Spinosaes, 1 part of Lignum Dalbergiae Odoriferae.
4. a kind of oral Chinese medicine compositions of treating apoplexy according to claim 2, composition and the weight portion of processing the crude drug of this medicine are 30 parts of the Radixs Astragali, 15 parts of Radix Angelicae Sinensis, 15 parts of Rhizoma Chuanxiongs, 10 parts of Radix Puerariaes, 10 parts of Radix Salviae Miltiorrhizaes; 10 parts of Hirudos; 10 parts of Scorpios, 10 parts of Pheretimas, 10 parts of Rhizoma Acori Graminei; 10 parts of Radix Curcumaes, 12 parts of Radix Codonopsis, 10 parts of Periostachum bombycis, 8 parts of Semen Ziziphi Spinosaes, 2 parts of Lignum Dalbergiae Odoriferaes.
5. like the arbitrary described pharmaceutical composition of claim 1-4; It is characterized in that getting crude drug; Add conventional adjuvant,, process clinical acceptable tablet, granule, pill, capsule, drop pill, soft capsule, slow releasing agent, oral liquid or lyophilized injectable powder according to common process.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210023514XA CN102552811B (en) | 2012-01-27 | 2012-01-27 | Oral Chinese medicine composition for treating apoplexy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210023514XA CN102552811B (en) | 2012-01-27 | 2012-01-27 | Oral Chinese medicine composition for treating apoplexy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102552811A true CN102552811A (en) | 2012-07-11 |
| CN102552811B CN102552811B (en) | 2013-05-29 |
Family
ID=46400265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210023514XA Expired - Fee Related CN102552811B (en) | 2012-01-27 | 2012-01-27 | Oral Chinese medicine composition for treating apoplexy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102552811B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102824619A (en) * | 2012-08-14 | 2012-12-19 | 王政乾 | Pharmaceutical composition for treating ischemic cerebrovascular diseases and preparation method thereof |
| CN103041119A (en) * | 2013-02-04 | 2013-04-17 | 刘学友 | Traditional Chinese medicine for treating cardiac disease |
| CN104984090A (en) * | 2015-07-03 | 2015-10-21 | 蔡涛 | Externally used traditional Chinese medicine cream for treating stroke hypertension |
| CN105287727A (en) * | 2015-10-28 | 2016-02-03 | 郭旺水 | Traditional Chinese medicine composition for treating apoplexy and preparing method and application thereof |
| CN108186986A (en) * | 2018-02-13 | 2018-06-22 | 刘国荣 | Treat Chinese medicine composition of cerebral apoplexy and its preparation method and application |
| CN110772606A (en) * | 2019-12-11 | 2020-02-11 | 孟胜喜 | Traditional Chinese medicine composition for preventing and treating ischemic stroke and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1223122A (en) * | 1998-01-13 | 1999-07-21 | 彭文瑞 | Medicine for curing cerebrovascular and cardiovascular diseases and preparation process thereof |
| CN101195016A (en) * | 2006-12-05 | 2008-06-11 | 陕西健民制药有限公司 | Medicament for treating apoplexy and technique of preparing the same |
-
2012
- 2012-01-27 CN CN201210023514XA patent/CN102552811B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1223122A (en) * | 1998-01-13 | 1999-07-21 | 彭文瑞 | Medicine for curing cerebrovascular and cardiovascular diseases and preparation process thereof |
| CN101195016A (en) * | 2006-12-05 | 2008-06-11 | 陕西健民制药有限公司 | Medicament for treating apoplexy and technique of preparing the same |
Non-Patent Citations (2)
| Title |
|---|
| 李鸿泓等: "中药治疗缺血性中风研究进展", 《山西中药》 * |
| 郭会军等: "中医药治疗中风的临床研究回顾", 《中国中医药现代远程教育》 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102824619A (en) * | 2012-08-14 | 2012-12-19 | 王政乾 | Pharmaceutical composition for treating ischemic cerebrovascular diseases and preparation method thereof |
| CN103041119A (en) * | 2013-02-04 | 2013-04-17 | 刘学友 | Traditional Chinese medicine for treating cardiac disease |
| CN103041119B (en) * | 2013-02-04 | 2015-11-18 | 刘学友 | One treats cardiopathic Chinese medicine |
| CN104984090A (en) * | 2015-07-03 | 2015-10-21 | 蔡涛 | Externally used traditional Chinese medicine cream for treating stroke hypertension |
| CN105287727A (en) * | 2015-10-28 | 2016-02-03 | 郭旺水 | Traditional Chinese medicine composition for treating apoplexy and preparing method and application thereof |
| CN108186986A (en) * | 2018-02-13 | 2018-06-22 | 刘国荣 | Treat Chinese medicine composition of cerebral apoplexy and its preparation method and application |
| CN110772606A (en) * | 2019-12-11 | 2020-02-11 | 孟胜喜 | Traditional Chinese medicine composition for preventing and treating ischemic stroke and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102552811B (en) | 2013-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102552811B (en) | Oral Chinese medicine composition for treating apoplexy | |
| CN1857690A (en) | Gynecopathy treating preparation and its preparing process | |
| CN101549088A (en) | Traditional Chinese medicine for treating neurasthenia and preparation method thereof | |
| CN101380372A (en) | Pharmaceutical composition for treating cervical vertebra disease and its preparation method | |
| CN101524437A (en) | Chinese medicinal composition for treating female anemia and preparation method thereof | |
| CN102008582B (en) | Angelica sinensis chengqi decoction and application thereof | |
| CN102512644A (en) | Traditional Chinese medicine composition for removing freckles and nourishing skin and preparation method for same | |
| CN102512649A (en) | Composition of Chinese medicinal herbs for treating postpartum blood stasis and preparation method thereof | |
| CN102895387B (en) | Kidney-yang-warming medicine composition, and preparation thereof and preparation method thereof | |
| CN105456818A (en) | Traditional Chinese medicine composition containing folium artemisiae argyi and being capable of treating insomnia and preparation method of traditional Chinese medicine composition | |
| CN1954877B (en) | Chinese medicinal composite for treating ischemic necrosis of femoral head and its preparation method | |
| CN105617251B (en) | Traditional Chinese medicine composition for treating depression and preparation method thereof | |
| CN103341095B (en) | Clysis liquid used for chronic renal failure | |
| CN102552537A (en) | Chinese medicinal composition for treating qi and blood loss | |
| CN103028034A (en) | Pharmaceutical composition for treating insomnia and preparation method | |
| CN102283993B (en) | Traditional Chinese medicine composition for treating systemic lupus erythematosus | |
| CN100428942C (en) | Heart-nourishing and tranquilizing medicine and its prepn process | |
| CN104983759A (en) | Traditional Chinese medicine composition treating diabetic nephropathy and preparing method thereof | |
| CN103751415B (en) | Traditional Chinese medicinal composition and preparation method thereof | |
| CN102824619A (en) | Pharmaceutical composition for treating ischemic cerebrovascular diseases and preparation method thereof | |
| CN103690785B (en) | A kind of oral Chinese medicine composition for the treatment of early high blood pressure disease | |
| CN103169887B (en) | Chinese patent medicine for improving sleep and preparation method of Chinese patent medicine | |
| CN105434790A (en) | Oral pharmaceutical composition used for treating ischemic cerebrovascular disease, and preparation method thereof | |
| CN102423367B (en) | Beautifying and blood-activating medicament | |
| CN106511896A (en) | Medicine for cerebral hemorrhage convalescent stage and preparation method of medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: HAIMEN JIANGHAI CONSTRUCTION INVESTMENT CO., LTD. Free format text: FORMER OWNER: WANG ZHENGQIAN Effective date: 20140416 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 264300 WEIHAI, SHANDONG PROVINCE TO: 226100 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140416 Address after: 226100, 999, Guangzhou Road, Haimen, Jiangsu, Nantong Patentee after: Haimen Jianghai Construction Investment Co.,Ltd. Address before: 264300 Shandong province Rongcheng Chengshan Middle Road No. 298 Patentee before: Wang Zhengqian |
|
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Ran Hongtu Inventor before: Wang Zhengqian Inventor before: Wang Dong |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170627 Address after: Zheng Jie 400050 Xiejiawan Jiulongpo District of Chongqing City No. 95 Building 2 unit 3 1-3 Patentee after: Ran Hongtu Address before: 312365 Zhejiang Province, Shaoxing city Shangyu District Songxia Town City Station International Plaza building 36 unit room 1-101 Patentee before: ZHEJIANG HONGSHENG TECHNOLOGY TRANSFER SERVICES CO.,LTD. Effective date of registration: 20170627 Address after: 312365 Zhejiang Province, Shaoxing city Shangyu District Songxia Town City Station International Plaza building 36 unit room 1-101 Patentee after: ZHEJIANG HONGSHENG TECHNOLOGY TRANSFER SERVICES CO.,LTD. Address before: 226100, 999, Guangzhou Road, Haimen, Jiangsu, Nantong Patentee before: Haimen Jianghai Construction Investment Co.,Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130529 Termination date: 20190127 |